NewYork-Presbyterian and AstraZeneca collaborate in series of cancer studies

NewsGuard 100/100 Score

NewYork-Presbyterian Hospital is one of six centers nationally to be selected for collaboration with AstraZeneca for an ongoing series of Phase II clinical trials of various novel compounds for potential treatment of a wide variety of cancers.

The aim of this unique and innovative approach, called E3 (Early Efficacy Enterprise), is to expedite development of new treatments by reducing the need for site selection and approval prior to each individual trial.

The series of studies will also involve rapid patient recruitment and assessment of outcome after treatment. By looking at the treatment results in defined patient populations, any early signal of efficacy of a compound can be identified.

"In close collaboration between the pharmaceutical company and both of the Hospital's major medical centers -- NewYork-Presbyterian/Columbia University Medical Center and NewYork-Presbyterian/Weill Cornell Medical Center -- we are committing ourselves to an all-out search for new cancer therapies," says Dr. Andrew Dannenberg, the E3 principal investigator for NewYork-Presbyterian. He is director of Cancer Prevention at NewYork-Presbyterian/Weill Cornell and the Henry R. Erle, M.D.–Roberts Family Professor of Medicine at Weill Cornell Medical College.

"New York-Presbyterian Hospital is one of the world leaders in cancer research," says Alan Barge, vice president of clinical oncology at AstraZeneca LP. "It is for this reason that we have selected them to be one of the sites for expedited clinical trials using AstraZeneca drugs."

The first three clinical trials will study the compounds AZD6244 and vandetanib (ZACTIMA) in diseases including pancreatic, non-small-cell lung, and colorectal cancer. The anticipated 12 to 15 studies to be done over the next five years of the E3 program will look at compounds for cancers, including breast and urologic.

As part of the partnership agreement, AstraZeneca will provide funding for the studies. and


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI chatbots outperform doctors in empathy and readability for cancer-related questions, study finds